UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 84

Sortiert nach

Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications

BMC cancer, 2020-05, Vol.20 (1), p.383-13, Article 383

2020

Link zum Volltext

Verfügbarkeit prüfen

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Journal for immunotherapy of cancer, 2021-08, Vol.9 (8), p.e002990

2021

Link zum Volltext

Verfügbarkeit prüfen

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Cancer Immunology, Immunotherapy, 2020-07, Vol.69 (7), p.1177-1187

2020

Link zum Volltext

Verfügbarkeit prüfen

Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival

Cancer Immunology, Immunotherapy, 2022-05, Vol.71 (5), p.1157-1165

2022

Link zum Volltext

Verfügbarkeit prüfen

Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer

Cancer Immunology, Immunotherapy, 2023-02, Vol.72 (2), p.339-350

2023

Link zum Volltext

Verfügbarkeit prüfen

Glycolate oxidase-1 gene variants influence the risk of hyperoxaluria and renal stone development

World journal of urology, 2024-01, Vol.42 (1), p.28-28, Article 28

2024

Link zum Volltext

Verfügbarkeit prüfen

CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1

Cancer Immunology, Immunotherapy, 2015-06, Vol.64 (6), p.677-688

2015

Link zum Volltext

Verfügbarkeit prüfen

Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events

Cancer Immunology, Immunotherapy, 2021-10, Vol.70 (10), p.2761-2769

2021

Link zum Volltext

Verfügbarkeit prüfen

Haplotype of CaSR gene is associated with risk of renal stone disease in West Indian population

Urolithiasis, 2022-12, Vol.51 (1), p.25-25, Article 25

2022

Link zum Volltext

Verfügbarkeit prüfen

Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer

Cancer Immunology, Immunotherapy, 2020-11, Vol.69 (11), p.2403-2408

2020

Link zum Volltext

Verfügbarkeit prüfen

Ante-mortem and Post-mortem Diagnosis Modalities and Phylogenetic Analysis of Rabies Virus in Domestic and Wild Animals of Gujarat, India

Indian journal of microbiology, 2023-12, Vol.63 (4), p.645-657

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2024-02, Vol.12 (2), p.e007340

2024

Link zum Volltext

Verfügbarkeit prüfen

Role of NF-κB in the pathogenesis of diabetes and its associated complications

Pharmacological reports, 2009-07, Vol.61 (4), p.595-603

2009

Link zum Volltext

Verfügbarkeit prüfen

Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Cancer Immunology, Immunotherapy, 2020-07, Vol.69 (7), p.1189-1189

2020

Link zum Volltext

Verfügbarkeit prüfen

524 A phase 2, multi-arm study of anti-CD47 antibody, magrolimab, in combination with docetaxel in patients with locally advanced or metastatic solid tumors

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A554-A554

2021

Link zum Volltext

Verfügbarkeit prüfen

A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer

Cancer chemotherapy and pharmacology, 2016-09, Vol.78 (3), p.577-584

2016

Link zum Volltext

Verfügbarkeit prüfen

380 Preliminary results of an ongoing phase I trial of FT500, a first-in-class, off-the-shelf, induced pluripotent stem cell (iPSC) derived natural killer (NK) cell therapy in advanced solid tumors

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A405-A405

2020

Link zum Volltext

Verfügbarkeit prüfen

Next generation predictive biomarkers for immune checkpoint inhibition

Cancer and metastasis reviews, 2017-03, Vol.36 (1), p.179-190

2017

Link zum Volltext

Verfügbarkeit prüfen

VP2 gene sequencing based Geno-grouping of infectious bursal disease viruses isolated from Gujarat and Maharashtra state (India)

Virusdisease, 2021-12, Vol.32 (4), p.823-829

2021

Link zum Volltext

Verfügbarkeit prüfen

Characterization of squalene synthase gene from Gymnema sylvestre R. Br

Beni-Suef University journal of basic and applied sciences, 2021-01, Vol.10 (1), p.6-11, Article 6

2021

Link zum Volltext

Verfügbarkeit prüfen

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer

BMC cancer, 2023-07, Vol.23 (1), p.708-708

2023

Link zum Volltext

Verfügbarkeit prüfen

531 A Phase 1b multi-tumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors: results of the triple-negative breast cancer, ovarian cancer, and endometrial cancer cohorts

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A562-A562

2021

Link zum Volltext

Verfügbarkeit prüfen

491 BASECAMP-1: an observational study to identify relapsed solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) and leukapheresis for future CAR T-cell therapy

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A522-A522

2021

Link zum Volltext

Verfügbarkeit prüfen

Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2018-09, Vol.6 (1), p.93-93, Article 93

2018

Link zum Volltext

Verfügbarkeit prüfen

756 First-in-human, open-label, multicenter, phase 1 clinical study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of anti Siglec-15 PYX-106 in subjects with advanced solid tumors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A852-A852

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 84

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLink

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(82)
Mit Volltextzugriff
(83)

Publikationsform

Sprache

Englisch
(84)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

SpringerNature Journals
(84)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(56)
EZB Electronic Journals Library
(47)
BMJ
(17)
Journals@Ovid
(16)
IngentaConnect Journals
(13)
IngentaConnect Journals
(3)
Single Journals
(3)
Wiley Online Library
(2)
Nexis Uni
(2)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival

Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer

Glycolate oxidase-1 gene variants influence the risk of hyperoxaluria and renal stone development

CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1

Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events

Haplotype of CaSR gene is associated with risk of renal stone disease in West Indian population

Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer

Ante-mortem and Post-mortem Diagnosis Modalities and Phylogenetic Analysis of Rabies Virus in Domestic and Wild Animals of Gujarat, India

Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors

Role of NF-κB in the pathogenesis of diabetes and its associated complications

Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

524 A phase 2, multi-arm study of anti-CD47 antibody, magrolimab, in combination with docetaxel in patients with locally advanced or metastatic solid tumors

A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer

380 Preliminary results of an ongoing phase I trial of FT500, a first-in-class, off-the-shelf, induced pluripotent stem cell (iPSC) derived natural killer (NK) cell therapy in advanced solid tumors

Next generation predictive biomarkers for immune checkpoint inhibition

VP2 gene sequencing based Geno-grouping of infectious bursal disease viruses isolated from Gujarat and Maharashtra state (India)

Characterization of squalene synthase gene from Gymnema sylvestre R. Br

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer

531 A Phase 1b multi-tumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors: results of the triple-negative breast cancer, ovarian cancer, and endometrial cancer cohorts

491 BASECAMP-1: an observational study to identify relapsed solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) and leukapheresis for future CAR T-cell therapy

Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors

756 First-in-human, open-label, multicenter, phase 1 clinical study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of anti Siglec-15 PYX-106 in subjects with advanced solid tumors

Aktive Filter

Suchergebnisse filtern